Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-091804
Filing Date
2024-08-06
Accepted
2024-08-06 16:10:29
Documents
75
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q dvax-20240630.htm   iXBRL 10-Q 2753681
2 EX-10.1 dvax-ex10_1.htm EX-10.1 301585
3 EX-10.2 dvax-ex10_2.htm EX-10.2 47666
4 EX-31.1 dvax-ex31_1.htm EX-31.1 14115
5 EX-31.2 dvax-ex31_2.htm EX-31.2 13831
6 EX-32.1 dvax-ex32_1.htm EX-32.1 8593
7 EX-32.2 dvax-ex32_2.htm EX-32.2 8747
  Complete submission text file 0000950170-24-091804.txt   11466781

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dvax-20240630.xsd EX-101.SCH 1589510
78 EXTRACTED XBRL INSTANCE DOCUMENT dvax-20240630_htm.xml XML 2125550
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34207 | Film No.: 241179309
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)